AstraZeneca PLC - American Depositary Shares (NQ:AZN)

92.77 UNCHANGED

Last Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2

...

28 29 30 31 32 33 34 35 36

...

75 76 Next >

United Airlines, Interactive Brokers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

October 18, 2023

U.S. stock futures traded lower this morning on Wednesday. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

FDA Approves Merck's Top Selling Drug, Keytruda For Expanded Use In Lung Cancer Indication ↗

October 17, 2023

The FDA approved Merck & Co Inc's (NYSE: MRK) Keytruda for resectable (tumors ≥4 centimeters [cm] or node-positive) non-small cell lung cancer (NSCLC) in combination with platinum-containing...

Via Benzinga

Pfizer, Sanofi's Respiratory Syncytial Virus Products Faces Insurance And Logistical Hurdles To Protect Infants ↗

October 16, 2023

As the respiratory virus season kicks off, healthcare providers are racing against time to offer Pfizer Inc's (NYSE: PFE) vaccine, Abrysvo, to pregnant patients and Sanofi SA's (NASDAQ:

Via Benzinga

Understanding AstraZeneca's Position In Pharmaceuticals Industry Compared To Competitors ↗

October 16, 2023

Via Benzinga

Bitcoin's ETF Approval Rumor, Pfizer Slashes Annual Outlook, Activist Shareholder Shakes Up News Corp's Status Quo: Today's Top Stories ↗

October 16, 2023

Benzinga Bitcoin Spiked On False ETF Approval Rumor

Via Benzinga

Topics ETFs

AstraZeneca Unusual Options Activity For September 28 ↗

September 28, 2023

Via Benzinga

AstraZeneca's Tagrisso-Chemo Combo Under FDA Priority Review For Most Common Form Of Lung Cancer ↗

October 16, 2023

AstraZeneca Plc's (NASDAQ: AZN) supplemental New Drug Application for Tagrisso (osimertinib) in combination with chemotherapy has been accepted and

Via Benzinga

TAGRISSO® Plus Chemotherapy Granted Priority Review in the US for Patients with EGFR-Mutated Advanced Lung Cancer

October 16, 2023

From AstraZeneca

Via Business Wire

Week In Review: Two China Biopharmas Announce Billion Dollar Deals ↗

October 14, 2023

MediLink Therapeutics out-licensed global rights for its antibody-drug conjugate candidate to BioNTech in a $1.1 billion agreement. Meanwhile, BioMap formed a collaboration with Sanofi in a deal with...

Via Talk Markets

New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review

October 13, 2023

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:PYXS),(NASDAQ:AZN),(NYSE:LLY),(NASDAQ:MRUS) EQNX::TICKER_END

Via FinancialNewsMedia

3 Healthcare Stocks To Make You The Millionaire Next Door: October Edition ↗

October 13, 2023

These are the healthcare stocks to buy as they represent companies investing in research and development for growth and value creation.

Via InvestorPlace

ABBV Stock: Buy for the Yield, Hold for This Other Reason ↗

October 13, 2023

"Safe harbor" status and a high, growing dividend yield isn't the only thing that's appealing with ABBV stock.

Via InvestorPlace

AstraZeneca Awards Funding to Eight Innovative Research Projects From Early-Career Scientists Around the World in Second R&D Postdoctoral Challenge

October 12, 2023

From AstraZeneca

Via Business Wire

AstraZeneca advances scientific leadership across multiple cancers with first data from four pivotal Phase III trials at ESMO

October 11, 2023

From AstraZeneca

Via Business Wire

Astrazeneca Foundation Awards 12 Nonprofit Organizations More Than $2M to Advance Health Equity

October 10, 2023

From AstraZeneca Foundation

Via Business Wire

2 Nasdaq 100 Stocks That Are Surefire Buys in October, and 1 to Avoid Like the Plague ↗

October 06, 2023

Two Nasdaq 100 components stand out as plain-as-day values, while another widely owned Nasdaq 100 stock may find it impossible to meet investors' lofty growth expectations.

Via The Motley Fool

Why Shares of Conduit Pharmaceuticals Are Jumping Wednesday ↗

October 04, 2023

The stock had a brief big rebound from a huge drop on Tuesday.

Via The Motley Fool

Drugmakers Agree To Participate For Medicare Drug Price Negotiation With Biden Administration ↗

October 03, 2023

All ten manufacturers of the first drugs selected for Medicare price negotiations will be participating, the White House said, even though many of them are suing the administration

Via Benzinga

'Airbnb Has Foundational Cracks', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft's Nadella Criticizes Google's Exclusive Content Deals: Today's Top Stories ↗

October 03, 2023

Benzinga

Via Benzinga

Why Cancer-Focused ALX Oncology Stock Gained Over 100% Today? ↗

October 03, 2023

ALX Oncology Holdings Inc (NASDAQ: ALXO) released prespecified interim Phase 2 data from its ASPEN-06 trial of evorpacept plus trastuzumab, Cyramza (ramucirumab) and paclitaxel for HER2-positive...

Via Benzinga

AstraZeneca Settles Heartburn Treatment Lawsuit For One Of Biggest Selling Drug ↗

October 03, 2023

AstraZeneca Plc (NASDAQ: AZN) has

Via Benzinga

Topics Lawsuit

Medicare Drug Price Negotiation - What Court's Decision Means for Americans ↗

October 02, 2023

A U.S. District Judge has upheld a pivotal initiative of President Joe Biden, giving the green light for Medicare to commence negotiations on prescription drug prices.

Via Benzinga

Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant ↗

October 02, 2023

Read the latest report on NanoViricides here

Via Benzinga

Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst ↗

September 28, 2023

Raymond James initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), a recent reverse merger with the old Magenta Therapeutics.

Via Benzinga

Pharma Giants Shift Stance, Embrace Medicare Negotiations Amid Rising Drug Costs ↗

September 28, 2023

AstraZeneca Plc (NASDAQ: AZN), Bristol Myers Squibb & Co (NYSE: BMY), and Boehringer Ingelheim are willing to participate in the initial round of Medicare drug price negotiation

Via Benzinga

Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges ↗

September 27, 2023

Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY

Via Benzinga

Biden's Urgent Action Against Antibiotic-Resistant Bacteria - Allocates $100M to Battle Deadly Superbugs ↗

September 27, 2023

U.S. President Joe Biden is set to unveil a $100 million research initiative to tackle the growing threat of drug-resistant bacteria. More than a million people worldwide succumb to infections caused...

Via Benzinga

Apple Defends Its $19B Google Search Deal, Hollywood's Writers Secure Credit For AI Training, China's Ambitious Chip Fund Faces Headwinds: Today's Top Stories ↗

September 27, 2023

Benzinga Alibaba's Logistics Arm Cainiao Files For Hong Kong IPO

Via Benzinga

Topics Artificial Intelligence

Weight Loss Drugs Like Wegovy Could Have Linked Anesthesia Complications, European Medicines Agency To Investigate ↗

September 27, 2023

The European Medicines Agency (EMA) is set to address concerns related to patients taking drugs such as Novo Nordisk A/S's (NYSE

Via Benzinga

Ionis Climbs On Late-Stage Trial Results For Body Fat Disorder ↗

September 26, 2023

IONS stock rose after Ionis said Olezarsen succeeded in reducing abnormally high levels of body fat inpatients with a rare genetic disorder.

Via Investor's Business Daily

< Previous 1 2

...

28 29 30 31 32 33 34 35 36

...

75 76 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.